Navigation Links
Study Shows No Standardized Approach to Epidural Steroid Injections for Back Pain
Date:1/28/2009

HONOLULU, Jan. 28 /PRNewswire/ -- Today at the American Academy of Pain Medicine's 25th Annual Meeting, researchers from University of California at San Diego report that no standardized practices exist for administering an epidural steroid injection for back pain. Researchers looked at many factors including: which steroids were given, the amount of steroid used, and whether or not a local anesthetic was mixed with the steroid.

Epidural steroid injections (ESI) are minimally invasive procedures used to treat pain in the neck, arms, back and legs caused by inflamed nerves. While injections in the lumbar (low back) region are low risk, injections in the thoracic (mid back) and cervical (neck) region have the risk of injury to the spinal cord and brain. It usually consists of a steroid diluted with sterile saline, and sometimes also addition of local anesthesia. Controversy exists on the long-term efficacy of this procedure to treat spine associated pain.

To compare currently taught techniques, Yogesh Patel, MD, and his colleagues at UCSD, identified and surveyed attending pain physicians at interventional pain programs in the United States about their protocols regarding ESI. Results showed that no standard protocols with regard to type of steroid, dose or use of local anesthesia exist. In fact, the data showed that while most physicians use a moderate volume and dose of steroid, some physicians are giving very high volumes (up to 10 cc) of steroids in areas such as the cervical epidural space. In limited enclosed areas like the cervical region that volume of medicine could lead to increased pressures which could potentially be painful for patients.

"Epidural steroid injections are an important and common option for the treatment of back pain. However, we found that a great variety of techniques are being used. There is no gold standard," said Dr. Patel, lead author of the study and resident at the University of California at San Diego. "Guidelines may need to be explored with regard to this procedure to increase the effectiveness and decrease risk when using this approach to treat pain."

Dr. Patel's study found there were differences from institution to institution regarding which steroid was preferred for these injections. The most common steroids identified for this procedure and respective dose ranges were: depomedrol (dose range 40-120 mg), celestone (dose range 6-15 mg), decadron (dose range 4-12 mg), and kenalog (dose range 10-80 mg).

"These variations in technique might affect why some patients get better results from ESI than others and may also explain good and poor outcomes. This needs to be explored further," Patel concluded.

    Poster Session Information (Poster 142)
    Begins: 3:30 PM (Hawaiian Time), Wednesday, January 28, 2009
    Ends: 10:00 AM (Hawaiian Time), Thursday, January 29, 2009
    Location: Coral Ballroom Foyer, Hilton Hawaiian Village

About the AAPM

For more than 25 years, the American Academy of Pain Medicine (AAPM) has been the medical specialty society representing more than 2,200 physicians practicing in the field of pain medicine. The Academy is involved in education, training, advocacy and research in the specialty of pain medicine. Information is available on the practice of pain medicine at http://www.painmed.org.


'/>"/>
SOURCE American Academy of Pain Medicine
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... , Dec. 9, 2016  RxWiki Inc., a digital ... digital marketing strategies of thousands of pharmacies through its ... Austin Inno,s "50 on Fire" Award in ... "We,re pleased to accept the award as one of ... Chief Executive Officer at RxWiki. "Our platform gives independent ...
(Date:12/8/2016)... , Dec. 8, 2016 IRIDEX Corporation (NASDAQ: ... newly issued shares of common stock, $0.01 par value (the ... underwritten public offering.  The final terms of the Offering will ... pricing, and there can be no assurance as to whether ... expects to use the net proceeds it will receive from ...
(Date:12/8/2016)... , Dec. 8, 2016 Global Interventional ... on the global interventional radiology market analyzes the ... report comprises an elaborate executive summary, including a ... segments and sub-segments. The research is a ... formed the bulk of our research efforts along ...
Breaking Medicine Technology:
(Date:12/9/2016)... - Cincinnati, Ohio (PRWEB) , ... December 09, ... ... the production of miniature, folded, pharmaceutical inserts and outserts. As a means ... Device. This addition will enable Flottman to individually code professional inserts (PIs) ...
(Date:12/9/2016)... ... December 09, 2016 , ... An inventor from Cana, Va., wanted to fulfill ... of amusement park rides. , The patent-pending SAFETY STRAP FOR AMPUTEES improves accessibility. It ... could be set up in a matter of minutes, or even seconds. The SAFETY ...
(Date:12/9/2016)... , ... December 09, 2016 , ... "I had a ... inventor from Winchester, Va. "I thought that if the nebulizer had a more child-friendly ... than fearing them." , He developed the patent-pending NEBY to avoid the need to ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Research Institute (WCRI) officially opened registration today for its 33rd Annual Issues ... Boston, MA . , The theme of the conference is “Persistent Challenges and ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Management (MTM), adherence, and other pharmacist-delivered patient care services, has announced the promotions ... Eric Hoessel to vice president of sales. , Litsinger joined Mirixa in ...
Breaking Medicine News(10 mins):